Abstract library

53 results for "eukaryotic translation initiation".
#1320 Are eIFs Ingredients for Neuroendocrine Tumorigenesis?
Introduction: Neuroendocrine tumors (NETs) develop in almost any organ, therefore they are a very heterogeneous group of tumors. One of the major activities in every cell is the translation of mRNA to the corresponding protein, which plays an important role in cancer development. Crucial for this translation process are eukaryotic initiation factors (eIFs), which are themselves regulated by the mammalian target of Rapamycin (mTOR)-pathway. Mutation or deregulated expression of eIFs influences cell growth and proliferation, contributing to carcinogenesis. The incidence of NETs has increased fivefold over the last three decades.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MSc. Nadine Gantenbein
#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Concetta Sciammarella
#1307 Expression of m-TOR Pathway Components in Gastric Neuroendocrine Neoplasms: A Pilot Study
Introduction: The mammalian target of rapamycin (mTOR) signaling pathway plays a key role in the regulation of cell proliferation, protein synthesis and neuroendocrine tumor growth.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Vera Delektorskaya
#2226 Approaching NETs from Many Angles: A Medical Research Paradigm to Challenge New Zealand’s Research Traditions
Introduction: NETwork! is a multidisciplinary clinical and translational research program investigating NETs from several perspectives.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Kate Parker
#1003 Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block
Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Patricia Grabowski
#2801 IMMUNeOCT: OCT LAR in the Induction of Immunologic Response in Patients with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study (EudraCT2017-001613-83)
Introduction: The possible impact of octreotide (OCT) Long-Acting Release (LAR) on the immune system regulation is largely unexplored.
Conference: 17th Annual ENETS Conference (2020)
Category: Biomarkers
Presenting Author: MD Alessandro Ottaiano
#2100 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design
Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Vincent Hautefeuille
Authors: Gueguen D, ...
#3009 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics
Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.
Conference: 17th Annual ENETS Conference (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Delphine Gueguen
#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard
#486 Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study
Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P<0.0001).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Anja Rinke
Authors: Rinke A, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team